ROBERT BAUMGARTNER V. - 24 Oct 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
/s/ Andrew Nick as Attorney-in-Fact for Robert V. Baumgartner pursuant to Power of Attorney previously filed.
Issuer symbol
TECH
Transactions as of
24 Oct 2024
Net transactions value
$0
Form type
4
Filing time
28 Oct 2024, 16:40:05 UTC
Previous filing
12 Aug 2024
Next filing
27 Aug 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Award $0 +1,462 +3.4% $0.000000 44,863 24 Oct 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Award $0 +3,511 $0.000000 3,511 24 Oct 2024 Common Stock 3,511 $68.37 Direct F1
holding TECH Stock Options (Right to Buy) 17,040 24 Oct 2024 Common Stock 17,040 $21.84 Direct
holding TECH Stock Options (Right to Buy) 15,940 24 Oct 2024 Common Stock 15,940 $25.30 Direct
holding TECH Stock Options (Right to Buy) 12,500 24 Oct 2024 Common Stock 12,500 $31.26 Direct
holding TECH Stock Options (Right to Buy) 7,592 24 Oct 2024 Common Stock 7,592 $44.96 Direct
holding TECH Stock Options (Right to Buy) 8,044 24 Oct 2024 Common Stock 8,044 $50.41 Direct
holding TECH Stock Options (Right to Buy) 6,028 24 Oct 2024 Common Stock 6,028 $63.92 Direct
holding TECH Stock Options (Right to Buy) 2,532 24 Oct 2024 Common Stock 2,532 $128.81 Direct
holding TECH Stock Options (Right to Buy) 3,460 24 Oct 2024 Common Stock 3,460 $73.94 Direct
holding TECH Stock Options (Right to Buy) 3,937 24 Oct 2024 Common Stock 3,937 $61.51 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.